Akebia Ther (AKBA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akebia Ther (AKBA) has a cash flow conversion efficiency ratio of 0.955x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($31.13 Million) by net assets ($32.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Akebia Ther balance sheet independence to measure how much of total assets are equity-financed.
Akebia Ther - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Akebia Ther's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Akebia Ther (AKBA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Akebia Ther Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Ther ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Dibay Electric Co Ltd
SHG:603320
|
0.023x |
|
Gladstone Land Corporation
NASDAQ:LAND
|
0.016x |
|
Altshuler Shaham Financial LTD
TA:ALTF
|
0.052x |
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
-0.192x |
|
Super Group Ltd.
JSE:SPG
|
0.109x |
|
Trifork Holding AG
CO:TRIFOR
|
0.035x |
|
Pollard Banknote Limited
TO:PBL
|
0.007x |
|
Beijing LabTech Instruments Co Ltd
SHG:688056
|
0.014x |
Annual Cash Flow Conversion Efficiency for Akebia Ther (2012–2025)
The table below shows the annual cash flow conversion efficiency of Akebia Ther from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Akebia Ther.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.61 Million | $67.99 Million | 2.085x | +152.22% |
| 2024-12-31 | $-49.19 Million | $-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | $-30.58 Million | $-23.38 Million | 0.765x | +105.47% |
| 2022-12-31 | $5.23 Million | $-73.15 Million | -13.987x | -309.22% |
| 2021-12-31 | $74.01 Million | $-252.97 Million | -3.418x | -666.73% |
| 2020-12-31 | $247.62 Million | $-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | $394.76 Million | $-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | $635.93 Million | $-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | $119.33 Million | $-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | $68.12 Million | $57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | $131.00 Million | $-52.41 Million | -0.400x | -51.50% |
| 2014-12-31 | $104.08 Million | $-27.48 Million | -0.264x | +28.33% |
| 2013-12-31 | $30.76 Million | $-11.33 Million | -0.368x | -113.69% |
| 2012-12-31 | $-2.68 Million | $-7.21 Million | 2.691x | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more